Susceptibility of cancer patients to Covid -19 infection [COVID-19]
Research type
Research Study
Full title
Susceptibility of cancer patients to Covid -19 infection as compared to the non-cancer population
IRAS ID
283233
Contact name
Akimfemi Akingboye
Contact email
Sponsor organisation
The Dudley Group NHS Foundation Trust
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
1 years, 3 months, 30 days
Research summary
December 2019, an outbreak of 2019 novel coronavirus disease (COVID-19) occurred in Wuhan, Hubei, which has been linked to the severe adult respiratory syndrome coronavirus 2 (SARS-CoV-2). It is characterized by rapid human-to-human transmission from droplet contamination. The clinical manifestations of COVID-19 ranges from; asymptomatic infection or mild, transient symptoms to severe viral pneumonia with respiratory failure. As many patients do not progress to severe disease the overall case fatality rate per infected individual is low, but hospitals in areas with significant community transmission have experienced a major increase in the number of hospitalized pneumonia patients, and the frequency of severe disease in hospitalized patients can be as high as 30%.\nPatients with cancer are often recalled to the hospital for treatment and monitoring, and hence, they may be at risk of contracting COVID-19. Moreover, cancer treatments such as chemotherapy and radiotherapy are immunosuppressive. Hence, the study will investigate the reported the incidence and outcomes of SARS-CoV-2 infection in cancer patients as compared to the rest of the patients equally infected with COVID-19. [Study relying on COPI notice] \n
REC name
East of England - Cambridgeshire and Hertfordshire Research Ethics Committee
REC reference
20/EE/0139
Date of REC Opinion
3 Jun 2020
REC opinion
Further Information Favourable Opinion